GS Carbon's ambition is to affect reductions in the carbon intensity of energy production and consumption by investing in carbon trading, developing and commercializing
advanced new decarbonization technologies, and by developing and owning renewable energy production assets.
Inspire and FAES intend to enter into a supply agreement in which FAES will supply to Inspire the bulk bilastine as active pharmaceutical ingredient (API) for Inspire's use in manufacturing, developing and commercializing
the bilastine compound in final form.
At present, Arrowhead owns majority interest in subsidiaries commercializing
diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials and carbon nanotube technology.
The company will continue to execute its strategy of building a patent portfolio related to carbon nanomaterials and commercializing
new carbon-based electronic products.
Arrowhead Research Corporation (Nasdaq:ARWR), announced today that its majority-owned subsidiary, Insert Therapeutics, a company commercializing
delivery-enhanced therapeutics using a patented class of polymeric systems, has treated its first patient in a Phase I study of IT-101, Insert's lead anti-cancer compound.
Arrowhead is now operating four majority-owned subsidiaries commercializing
nanotechnologies in the fields of nanomedicine, nanoelectronics, and nanomaterials.